Thinking of Launching a Companion Diagnostic? Ask Yourself These Questions | Diaceutics

Thinking of Launching a Companion Diagnostic? Ask Yourself These Questions

May 17th, 2016


For the last decade or so, much attention has been focused on personalized medicine; a modern approach that uses an individual’s genetic make-up to create a more targeted therapy or treatment. This advancement in genetics and biochemistry promises to bring to light the factors that explain why some patients largely benefit from therapy while others do not; and even in some cases go ahead to experience undesirable side effects.

To ensure better benefits for patients with the bonus of maximizing the potential of the companion diagnostic launch alongside a therapy, where should the focus be from the pharma company perspective? More importantly, are you asking the right questions to start with? Here are some example questions that should be considered early on:

1. Do you really comprehend the value that a diagnostic brings to your drug?

A companion diagnostic can help to select the patients that are most likely to give cleaner data and therefore reduce not only the sample sizes needed for trials but also the development costs incurred. In some instances, a diagnostic could even help save a patient from getting a drug that would otherwise fail. The market size may also be increased if the diagnostic identifies suitable patients that are getting an alternate drug.

2. Have you taken into account all the adoption hurdles that diagnostics face?

During the launch, confidence in a diagnostic may not be at the same desired level as a drug and therefore the relevance of chosen biomarkers to clinical outcomes may still not be considered direct or 100% predictive. Additionally, even if the test is ready, the physicians in the clinic may still be very reluctant to immediately accept the diagnostic without robust evidence and education.

3. Is it important to have a team for the product launch?

Having a team is very important when designing a commercial strategy as well as the associated tactical plans. The team should incorporate people who really know both the therapeutic and the diagnostic components. This should help to avoid potential miscommunication between the two siloed organizations that might otherwise be working independently on the diagnostic and the drug. This also ensures you have a shared direction and set of goals that work well for both parts of your product.

4. When do I need to start planning the launch?

Many companies have made the mistake of planning the launch too late and getting overwhelmed by the complexity of the process. Therefore, start your planning process early enough for a successful launch.

Launch Planner Free Demo

Webinars & Podcasts

July 5th, 2019
Liquid Biopsy in NSCLC
August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications